Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO.
San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases.
Get the full story at our sister site, Drug Delivery Business News.
Appelo is slated to join the Amsterdam-based company’s executive committee on July 18. He will succeed Sophie Bechu as chief operations officer, who will continue to work on project-based initiatives until her retirement in January 2023.
Appelo previously worked as the interim supply chain officer and has worked with private equity firms in the medtech industry. Prior to that, he was the VP of supply chain strategy, innovation and development and VP of supply chain medical devices at Johnson & Johnson.
“I am very pleased that Wim Appelo will be joining Philips as our new Chief Operations Officer,” CEO Frans van Houten said in a news release. “Wim brings a wealth of relevant experience to Philips, adding in-depth knowledge and understanding of medical technology and informatics supply ch…
BD (NYSE:BDX) announced today that it appointed Simon Campion as EVP and president of the company’s medical segment.
Franklin Lakes, New Jersey-based BD announced in March that Alberto Mas, who held the same roles Campion will assume, intended to retire. Campion’s position will be made effective on July 1, 2022.
Mas, 60, informed the company of his intent to retire in a move that will be made effective at the end of the company’s fiscal year on Sept. 30, 2022. He spent a total of nearly 30 years at BD across a number of leadership positions.
Campion will report to Chair, CEO and President Tom Polen and his responsibilities include global strategic, operational and commercial performance for the medical segment at BD, according to a news release. He has served as EVP and president of the interventional segment for BD since September 2018 and will continue to lead that business in the interim until the company names a successor.
Be…
Titan Medical (Nasdaq:TMDI) announced today that executive Perry Genova will depart the company effective immediately.
Genova, who served as senior VP of research and product development, will leave Titan following what the single access robotic-assisted surgery technology developer described as careful consideration and a review of the company’s future needs.
“As we transform from a technology research and development company to a company focused on regulatory clearance and commercialization, our needs continue to evolve,” Titan interim President, CEO and Chair Paul Cataford said in a news release. “We wish Perry success in his future endeavors.“
Titan Medical develops the Enos robotic single-access surgical system with an ergonomic focus. The company aims to provide a surgical experience that imitates a surgeon’s real-life movements, with multi-articulating instruments, dexterity and the ability to exert the forces necessary to complete everyday …
U.S. Dept. of Health and Human Services (HHS) announced that it formed a new research project agency for health.
HHS Secretary Xavier Becerra announced the formal establishment of the Advanced Research Project Agency for Health (ARPA-H) as an independent entity within the National Institutes of Health (NIH). Adam H. Russell was appointed as acting deputy director, effective next month.
Get the full story at our sister site, Drug Discovery & Development.
Rainville’s role includes leading the growth of Milpitas, California-based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings.
Get the full story at our sister site, Drug Delivery Business News.
Seattle-based Know Labs — which aims to make the first non-invasive glucose monitor cleared by the FDA — added Steven Kent as its new chief product officer, along with Peter Conley as its CFO and SVP of intellectual property.
Get the full story at our sister site, Drug Delivery Business News.
AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today.
The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain.
Pratt oversees supply chain issues as SVP in AdvaMed’s global policy department.
“Without access to component parts, ranging from high-tech semiconductor chips to basic papers and resins, our members are struggling to meet the demands of our health care system, potentially impacting the health and wellbeing of millions of Americans,” she said in a news release. “I am grateful for the opportunity to work with members of this public-private working group to address issues impacting our industry and to help ensure our supply chain is secure for patients in need.”
AdvaMed President and…
Bakul Patel in 2016, when he was the associate director for digital health in the FDA’s Center for Devices and Radiological Health [FDA photo by Michael Ermarth]
Former FDA Chief Digital Health Officer Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency.Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn.
Patel recounted highlights of his “incredible journey since 2008” at the FDA, including the introduction of functionality-based regulations in the FDA’s mobile medical apps guidance, working with international agencies to define and regulate software-as-a-medical-device (SaMD), developing the Digital Health Software Precertification (Pre-Cert) Program and launching the Digital Health Center of Excellence.
Patel had only been in his…
Accuray (NSDQ:ARAY) today announced it appointed Sandeep Chalke as senior VP and chief commercial officer, effective May 16.
Chalke will report to President and forthcoming CEO Suzanne Winter and will be responsible for the global commercial, product development, R&D and engineering functions of the Sunnyvale, California-based company.
“I am thrilled to join the Accuray team and have been impressed with the organization’s passion and commitment to creating a better future for cancer patients through technology innovation and advancing radiation therapy care. I look forward to leading the company’s efforts to drive patient access, gain market share and create long-term value for all stakeholders,” Chalke said in a news release.
Chalke has more than 25 years of medical device expertise in commercialization, business development and operations for a number of medtech segments, including interventional catheterization systems, dia…
The future for Insulet (Nasdaq:PODD) has a much different look on some level than it did about a week ago.
A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced that she would step down as the company’s president and CEO for personal reasons.
Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin delivery system developer, and will assume an advisory role to support the leadership transition to former ResMed President of Sleep and Respiratory Care Jim Hollingshead, who will succeed her.
While the executive makeup will change come June 1, Insulet’s efforts to innovate in the diabetes space won’t be halted, as the company will continue to plug along under new leadership, EVP of Innovation and Strategy Eric Benjamin said during a keynote event at DeviceTalks Boston.
Get the full story at our sister site, Drug Delivery Business News.
Thibaut Mongon — EVP and Worldwide Chair of Consumer Health at Johnson & Johnson since 2019 — will be CEO of the business when it spins out as a stand-alone company.
J&J (NYSE: JNJ) expects the spinoff to be complete in 2023, subject to legal requirements, including consultation with works councils and employee representatives.
“Thibaut is a visionary and respected global leader, whose consumer-centric mindset has repeatedly propelled the business forward. Under his leadership, the Consumer Health business of Johnson & Johnson has advanced its innovation to reach consumers with products that truly make a difference in their personal health, while simultaneously delivering healthy financial results,” Executive Chair Alex Gorsky said in a news release.